Gritstone posts ‘one of the most potent immunogenic-responses for a neoantigen vaccine’
Two patients with gastroesophageal cancer responded well to Gritstone Oncology’s immune-stimulating treatment in an early trial.
Elevar Announces Results from the Angel Trial, A Study of Monotherapy Rivoceranib (Apatinib) In Late-Stage Gastric Cancer Patients
At ESMO 2019, Elevar Therapeutics announced that in a phase 3 trial in gastric cancer patients, rivoceranib did not improve overall survival... Read More
Checkpoint Inhibitor Checks in as Treatment for Advanced Gastric Cancers
Despite mixed results in clinical trials, Keytruda is producing promising survival results in some gastric cancer patients and has promise in combination... Read More
Predictors of Response to Immune Checkpoint Inhibitors in Patients With Advanced Esophagogastric Cancer
In a recent trial of checkpoint inhibitors in gastric or esophageal cancer, patients who reported immune-related side effects also showed longer survival... Read More
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Leap Therapeutics announced that a combination of its experimental drug DKN-01 and Merck’s Keytruda had a 50% overall response rate in patients... Read More
Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study
In a trial involving 949 patients with 40 tumor types, including gastric cancer, a blood test from Guardant Health was as good... Read More
New Combination Shows Early Promise in Gastric Cancer
A combo of the immuno-oncology drug Keytruda with the VEGFR-2 inhibitor Cyramza was well tolerated by gastric cancer patients in a phase... Read More
Perioperative FOLFIRINOX for Gastroesophageal Adenocarcinoma
In a trial, the chemotherapy regimen FOLFIRINOX produced response rates on par with FLOT and may be easier to tolerate, says Dan... Read More
Chemo-Refractory Gastric Cancer Treated With Toripalimab
In a trial of the investigational PD-1 antibody toripalimab, gastric cancer patients with a high tumor mutational burden showed superior overall survival... Read More
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma
Adding Tykerb to chemotherapy in HER-2 positive gastric cancer patients was proven safe in a phase 2 trial